ALNYLAM PHARMACEUTICALS, INC. Foreign Pre-Tax Income
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Foreign Pre-Tax Income of $304.85 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign · last filed 2026-02-12
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2025 was $304.85M, a 56.70% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2024 was $194.55M, a 1058.46% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2023 was $16.79M, a 22.29% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2022 was $21.61M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Foreign 12 month | Income (Loss) from Continuing Operations before Income Taxes, Foreign 12 month as first filed |
|---|---|---|
| 2025-12-31 | $304.85M 10-K · filed 2026-02-12 | |
| 2024-12-31 | $194.55M 10-K · filed 2026-02-12 | |
| 2023-12-31 | $16.79M 10-K · filed 2026-02-12 | |
| 2022-12-31 | $21.61M 10-K · filed 2025-02-13 | |
| 2021-12-31 | -$57.41M 10-K · filed 2024-02-15 | |
| 2020-12-31 | -$172.74M 10-K · filed 2023-02-23 | |
| 2019-12-31 | -$287.65M 10-K · filed 2022-02-10 | -$288.51M 10-K · filed 2020-02-13 |
| 2018-12-31 | -$187.43M 10-K · filed 2021-02-11 | |
| 2017-12-31 | -$112.58M 10-K · filed 2020-02-13 | |
| 2016-12-31 | -$59.40M 10-K · filed 2019-02-14 | |
| 2015-12-31 | -$44.39M 10-K · filed 2018-02-15 | |
| 2014-12-31 | -$28.47M 10-K · filed 2017-02-15 | |
| 2013-12-31 | -$10.81M 10-K · filed 2016-02-12 | |
| 2012-12-31 | -$186.00K 10-K · filed 2015-02-13 | |
| 2011-12-31 | -$168.00K 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |